Seeking Alpha

Fate Therapeutics jumps in debut

  • Fate Therapeutics (FATE +13%) opens at $6.56 and moves sharply higher.
  • The offering priced at the low-end of its expected range, notable because the company had already lowered the range to $6-8 from $14-16.
  • FATE's lead product is ProHema, a hematopoietic stem cell therapeutic derived from umbilical cord blood.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)